Supporting the utility of this treatment, endogenous EPO is abnormally low in the cerebrospinal fluid (CSF) of SCA2 patients [116], and EPO has been shown to have an additional neurotrophic role [117]. This evidence concerns the gene EPO and spinocerebellar ataxia type 2.